2025-06-03-Bernstein-格雷斯海姆（GXI）_格雷斯海姆_三个季度内第二次盈利预警后评级下调_下一次是什么时候_20页_1mb

Gerresheimer Analysis Summary

⚖️ Rating & Price Target

Delphine Le Louet downgrades Gerresheimer's rating from Outperform (OLD 84.50 EUR) to Underperform, cutting the price target from €84.50 to €47.50, a 43% reduction in target.

📉 Reasons for Downgrade

• FY25 Guidance Cuts:

  • Revenue growth revised from 10-15% to 1-2% (down 9 percentage points), adj. EBITDA margin from >22% to ≈20%, EPS revised from high single-digit growth to low double-digit decline.
  • Cosmetics segment remains subdued, oral medication demand seen as temporary but declining. Dividend proposed at €0.04 (OLD €1.25).

• Analyst Call Criticism:

  • Company failed to address key questions (e.g., oral liquid business size, cosmetics losses) and provided vague 2H25 outlook.
  • Stylegal entity formation for Bormioli Pharma delayed, no clarity on Syringes tender process.

• Performance & Financial Pressures:

  • FCF forecast: -€99m (previously positive), low IRR of 19.8% for PE acquisition (insufficient for typical PE deals).
  • Debt leverage ratio persists, adj. EBITDA 4.1x (vs benchmark 3x).

📊 Key Financial Metrics (2024-2029)

⬇️ Revenue Growth: 8.9% CAGR (NEW) vs 9.4% (OLD).
⬇️ Adj. EBITDA Margin: 20.6% (2025E) vs 22.2% (OLD).
⬇️ EPS: Expected €4.31 (current estimate) vs €5.28 (OLD).

💰 Valuation & Peer Comparison

• EV/Sales: Traded at 1.2x (2025E) vs industry avg. 4.2x.
• P/E: 11.3x (2025E) vs 5y avg. 16.5x.
• Below peer valuation (EV/EBITDA: Gerresheimer 6.0x, avg. 15.8x). .

📈 Upside Risks & Outlook

• Fulfilling Bormioli synergy projections despite delays.
• GLP-1 biologics growth potential.

💎 Conclusion

Bernstein highlights management execution concerns and limited near-term盈利 prospects. Current valuation and financial strain suggest no near-term PE interest, heavy reliance on execution turnarounds for recovery.

Note: This summary emphasizes upgraded key information, downplaying repetitive content from exhibits replicating analysis facts.